Progress of enhancing the function of chimeric antigen receptor T-cells in replased/refractory B-cell malignancies / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 508-512, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-907206
ABSTRACT
When chimeric antigen receptor T cells (CAR-T) failed to treat relapsed and refractory B-cell malignancies, some researchers try to improve the efficacy by enhancing the function of CAR-T. It is a new hotspot of drug development and clinical research, and significant achievements have been made in this area recently. Multi-targeted CAR-T, lenalidomide, decitabine, programmed death 1 inhibitor and ibrutinib can all enhance the function of CAR-T. This article reviews the recent progress of enhancing the function of CAR-T in relapsed and refractory B-cell malignancies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS